Excess aldosterone under normal salt diet induces cardiac hyperthrophy and infiltration via oxidative stress

Hypertension Research

Volumn 28, Issue 5, 2005, Pages 447-455

  Yoshida, Kaoru ^a   Kim Mitsuyama, Shokei ^a,b   Wake, Ryotaro ^a   Izumiya, Yasuhiro ^a   Izumi, Yasukatsu ^a   Yukimura, Tokihito ^a   Ueda, Makiko ^a   Yoshiyama, Minoru ^a   Iwao, Hiroshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Aldosterone; Angiotensin II; Cardiac hypertrophy; Inflammation; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONIST; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; SODIUM CHLORIDE; SPIRONOLACTONE; SUPEROXIDE DISMUTASE; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG TARGETING; ECHOCARDIOGRAPHY; GENE EXPRESSION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; INFLAMMATION; MACROPHAGE; MALE; MYOCARDITIS; NONHUMAN; OSMOTIC MINIPUMP; OXIDATIVE STRESS; PATHOPHYSIOLOGY; RAT; SALT INTAKE; SALT LOADING; UNINEPHRECTOMY;

ACETYLCYSTEINE; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CHEMOKINE CCL2; ECHOCARDIOGRAPHY; HYPERALDOSTERONISM; MALE; MYOCARDITIS; OSTEOPONTIN; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SIALOGLYCOPROTEINS; SODIUM CHLORIDE, DIETARY;

EID: 22444431979     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.28.447     Document Type: Article

References (31)

1. Sato A, Hayashi M, Saruta T: Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. [i#Hypertens Res#1i] 2002; [b#25#1b]: 837-842.
2. Sato A, Saruta T: Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. [i#Hypertens Res#1i] 2004; [b#27#1b]: 303-310.
3. Iwashima Y, Horio T, Kuroda S, Takishita S, Kawano Y: Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension. [i#Hypertens Res#1i] 2002; [b#25#1b]: 49-56.
4. Gerling IC, Sun Y, Ahokas RA, [i#et al#1i]: Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cardiac phenotype. [i#Am J Physiol Heart Circ Physiol#1i] 2003; [b#285#1b]: H813-H821.
5. Pitt B, Remme W, Zannad F, [i#et al#1i]: Eplerenone, a selective aldosterone, blocker, in patients with left ventricular dysfunction after myocardial infarction. [i#N Engl J Med#1i] 2003; [b#348#1b]: 1309-1321.
6. Pitt B, Zannad F, Remme WJ, [i#et al#1i]: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. [i#N Engl J Med#1i] 1999; [b#341#1b]: 709-717.
7. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. [i#Endocrinology#1i] 2002; [b#143#1b]: 4828-4836.
8. Rocha R, Rudolph AE, Frierdich GE, [i#et al#1i]: Aldosterone induces a vascular inflammatory phenotype in the rat heart. [i#Am J Physiol Heart Circ Physiol#1i] 2002; [b#283#1b]: H1802-H1810.
9. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT: Aldosterone-induced inflammation in the rat heart: role of oxidative stress. [i#Am J Pathol#1i] 2002; [b#161#1b]: 1773-1781.
10. Weber KT: Aldosterone in congestive heart failure. [i#N Engl J Med#1i] 2001; [b#345#1b]: 1689-1697.
11. Weber KT, Sun Y, Guarda E: Structural remodeling in hypertensive heart disease and the role of hormones. [i#Hypertension#1i] 1994; [b#23#1b]: 869-877.
12. Rossi GP, Di Bello V, Ganzaroli C, [i#et al#1i]: Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. [i#Hypertension#1i] 2002; [b#40#1b]: 23-27.
13. Rossi GP, Sacchetto A, Visentin P, [i#et al#1i]: Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. [i#Hypertension#1i] 1996; [b#27#1b]: 1039-1045.
14. Ganguly A: Primary aldosteronism. [i#N Engl J Med#1i] 1998; [b#339#1b]: 1828-1834.
15. Park JB, Schiffrin EL: Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. [i#Am J Hypertens#1i] 2002; [b#15#1b]: 164-169.
16. Chatterjee PK, Cuzzocrea S, Brown PA, [i#et al#1i]: Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat. [i#Kidney Int#1i] 2000; [b#58#1b]: 658-673.
17. Nishiyama A, Yao L, Nagai Y, [i#et al#1i]: Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. [i#Hypertension#1i] 2004; [b#43#1b]: 841-848.
18. Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD, Webb RCZ: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. [i#Hypertension#1i] 2001; [b#37#1b]: 781-786.
19. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL: Spironolactone improves angiotensin-induced vascular changes and oxidative stress. [i#Hypertension#1i] 2002; [b#40#1b]: 504-510.
20. Kim S, Izumi Y, Izumiya Y, Zhan Y, Taniguchi M, Iwao H: Beneficial effects of combined blockade of ACE and AT1 receptor on intimal hyperplasia in balloon-injured rat artery. [i#Arterioscler Thromb Vasc Biol#1i] 2002; [b#22#1b]: 1299-1304.
21. Izumiya Y, Kim S, Izumi Y, [i#et al#1i]: Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. [i#Circ Res#1i] 2003; [b#93#1b]: 874-883.
22. 2-terminal kinase activation in cardiac hypertrophy in hypertensive rats. [i#Hypertension#1i] 2000; [b#36#1b]: 511-516.
23. Kim S, Yoshiyama M, Izumi Y, [i#et al#1i]: Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. [i#Circulation#1i] 2001; [b#103#1b]: 148-154.
24. Selye H: The general adaptation syndrome and the diseases of adaptation. [i#J Clin Endocrinol Metab#1i] 1946; [b#6#1b]: 117-230.
25. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. [i#Cardiovasc Res#1i] 1992; [b#26#1b]: 671-677.
26. Robert V, Silvestre JS, Charlemagne D, [i#et al#1i]: Biological determinants of aldosterone-induced cardiac fibrosis in rats. [i#Hypertension#1i] 1995; [b#26#1b]: 971-978.
27. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. [i#J Lab Clin Med#1i] 1992; [b#120#1b]: 893-901.
28. Sun Y, Ramires FJ, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. [i#Cardiovasc Res#1i] 1997; [b#35#1b]: 138-147.
29. Campbell SE, Janicki JS, Weber KT: Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. [i#J Mol Cell Cardiol#1i] 1995; [b#27#1b]: 1545-1560.
30. Ahokas RA, Warrington KJ, Gerling IC, [i#et al#1i]: Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. [i#Circ Res#1i] 2003; [b#93#1b]: e124-e135.
31. Zafarullah M, Li WQ, Sylvester J, Ahmad M: Molecular mechanisms of [i#N#1i]-acetylcysteine actions. [i#Cell Mol Life Sci#1i] 2003; [b#60#1b]: 6-20.